Ekot (with Audio), Första patienten i Sverige har fått nytt covid-läkemedel

Första patienten i Sverige har fått nytt covid-läkemedelLyssna från tidpunkt:

2021-03-03 04:48:00

För första gången har en covid-patient i Sverige behandlats med det nya antivirala läkemedlet bamlanivimab. Det rapporterar Svt nyheter.

Läkemedlet består av konstgjorda antikroppar som ges med dropp och fick en så kallad beredskapslicens i mitten av februari.

Den första ordinarie leveransen av bamlanivimab kommer till Sverige i nästa vecka.

Try LingQ and learn from Netflix shows, Youtube videos, news articles and more.

@import url(https://fonts.googleapis.com/css2?family=Rubik:wght@700&display=swap);body.is-unscrollable{overflow-y:hidden}body .lqp{position:relative;font-family:Rubik,BlinkMacSystemFont,-apple-system,"Segoe UI",Roboto,Oxygen,Ubuntu,Cantarell,"Fira Sans","Droid Sans","Helvetica Neue",Helvetica,Arial,sans-serif!important;font-weight:700;-webkit-box-sizing:border-box;box-sizing:border-box;color:#fff;overflow:hidden;width:520px;max-width:calc(100vw - 32px);background-color:#091a2f;-webkit-transition:-webkit-transform .34s cubic-bezier(1,-.2,.6,1);transition:-webkit-transform .34s cubic-bezier(1,-.2,.6,1);transition:transform .34s cubic-bezier(1,-.2,.6,1);transition:transform .34s cubic-bezier(1,-.2,.6,1),-webkit-transform .34s cubic-bezier(1,-.2,.6,1);-webkit-transform:translateY(-112vh);-ms-transform:translateY(-112vh);transform:translateY(-112vh);padding:32px 16px 0;margin:10vh 16px}body .lqp *{margin:0;padding:0;border:none;outline:0;line-height:1.2em}body .lqp-wrap{z-index:9999999999;visibility:hidden;position:fixed;display:-webkit-box!important;display:-ms-flexbox!important;display:flex!important;-webkit-box-orient:vertical;-webkit-box-direction:normal;-ms-flex-direction:column;flex-direction:column;-webkit-box-align:center;-ms-flex-align:center;align-items:center;overflow-x:hidden;overflow-y:auto;top:0;left:0;right:0;bottom:0;-webkit-transition:opacity .5s ease-out,visibility 0s .5s;transition:opacity .5s ease-out,visibility 0s .5s}body .lqp-wrap:not(.is-open) .lqp-app-screen{-webkit-transform:translateY(100%);-ms-transform:translateY(100%);transform:translateY(100%)}body .lqp-wrap.is-open{visibility:visible!important;opacity:1!important;-webkit-transition:opacity .5s ease-out,visibility 0s 0s;transition:opacity .5s ease-out,visibility 0s 0s}body .lqp-wrap.is-open .lqp{-webkit-transform:translate(0);-ms-transform:translate(0);transform:translate(0);-webkit-transition:-webkit-transform .5s cubic-bezier(0,0,0,1.1);transition:-webkit-transform .5s cubic-bezier(0,0,0,1.1);transition:transform .5s cubic-bezier(0,0,0,1.1);transition:transform .5s cubic-bezier(0,0,0,1.1),-webkit-transform .5s cubic-bezier(0,0,0,1.1)}body .lqp-wrap.is-open .lqp-bg{opacity:.78}body .lqp-close{position:absolute;display:-webkit-box;display:-ms-flexbox;display:flex;z-index:5;cursor:pointer;top:0;right:0;padding:12px;border-radius:50%;background-color:transparent;opacity:.6}body .lqp-body{display:grid}body .lqp-content{padding-bottom:32px}body .lqp-offer-1{font-size:26px;margin-bottom:4px;margin-bottom:4px}body .lqp-offer-2{font-size:36px;color:#478ef7}body .lqp-offer-3{font-size:36px}body .lqp-title{margin-bottom:24px}body .lqp-bg{position:fixed;z-index:-2;background-color:#000;opacity:0;top:0;left:0;right:0;bottom:-30vh;-webkit-transition:.32s ease-out;transition:.32s ease-out}body .lqp-anim-text{position:relative;display:inline-block;color:#fbb718!important;vertical-align:text-top;overflow:hidden;height:1em;vertical-align:text-top}body .lqp-cta{font-size:18px;display:inline-grid;-webkit-box-pack:center;-ms-flex-pack:center;justify-content:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;min-height:48px;min-width:243px;color:#091a2f;background-color:#fbb718;border:1px solid #fbb718;border-radius:80px;text-decoration:none;margin-top:24px;-webkit-transition:color .1s ease-out,background-color .1s ease-out;transition:color .1s ease-out,background-color .1s ease-out}body .lqp-anim-list{display:block!important;-webkit-transition:-webkit-transform .3s ease-in-out;transition:-webkit-transform .3s ease-in-out;transition:transform .3s ease-in-out;transition:transform .3s ease-in-out,-webkit-transform .3s ease-in-out}body .lqp-anim-item{margin:0!important;padding:0!important}body .lqp-bg-imgs svg{position:absolute;z-index:-1;bottom:0;right:0}body .lqp-app-screen{-webkit-transform:translateY(0);-ms-transform:translateY(0);transform:translateY(0);-webkit-transition:-webkit-transform .38s 40ms ease-out;transition:-webkit-transform .38s 40ms ease-out;transition:transform .38s 40ms ease-out;transition:transform .38s 40ms ease-out,-webkit-transform .38s 40ms ease-out;background-position:top center;background-size:100% auto;background-repeat:no-repeat;margin:0 auto}body .lqp-app-screen img{max-width:100%!important;vertical-align:middle}html body.is-unscrollable{overflow-y:hidden!important}@media only screen and (min-width:769px){body .lqp{width:946px;padding:46px 32px 0;margin:20vh 16px}body .lqp-body{grid-template-columns:auto auto;grid-gap:32px}body .lqp-content{padding-bottom:68px}body .lqp-offer-1{font-size:33px}body .lqp-offer-2{font-size:44px}body .lqp-offer-3{font-size:42px}body .lqp-app-screen{display:block;position:relative;width:302px;height:100%}}@media only screen and (min-width:932px){body .lqp{padding:54px 68px 0;margin:18vh 16px}body .lqp-close{padding:24px;-webkit-transition:-webkit-transform .2s ease;transition:-webkit-transform .2s ease;transition:transform .2s ease;transition:transform .2s ease,-webkit-transform .2s ease}body .lqp-close:hover{-webkit-transform:rotate(90deg);-ms-transform:rotate(90deg);transform:rotate(90deg);opacity:1}body .lqp-offer-1{font-size:36px}body .lqp-offer-3{font-size:52px}body .lqp-cta:hover{background-color:#091a2f;color:#fff}}@media only screen and (max-width:768px){body .lqp-content{text-align:center;padding-bottom:42px}body .lqp-bg-imgs svg{width:100%;height:auto}body .lqp-app-screen{width:254px;height:263px}}@media only screen and (max-width:768px) and (max-width:768px){body .lqp-bg-imgs svg#bg-radial{width:auto;height:72%;max-height:492px}}@media only screen and (max-width:371px){body .lqp-offer-1{font-size:24px}body .lqp-offer-2{font-size:32px}body .lqp-offer-3{font-size:32px}}

Ekot (with Audio), Första patienten i Sverige har fått nytt covid-läkemedel

Want to learn szwedzki? Start now!

Want to learn szwedzki?
Start now!